MAIA Biotechnology Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. MAIA Biotechnology Inc. is based in CHICAGO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-22.40M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -211.15% |
| Return on Assets (Trailing 12 Months) | -126.26% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.51 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.70 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.62 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.83M |
| Free Float | 48.78M |
| Market Capitalization | $83.34M |
| Average Volume (Last 20 Days) | 0.37M |
| Beta (Past 60 Months) | 0.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.81% |
| Percentage Held By Institutions (Latest 13F Reports) | 5.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |